2016•Journal watchRequires access
Tocilizumab Might Be an Option for Managing Giant Cell Arteritis
Jonathan S. Coblyn
Open publisher page 0 citations
Abstract
The standard of care for patients with giant cell arteritis (GCA) is steroid therapy. However, prolonged courses of steroids often are required, leading to substantial steroid-associated complications. Until now, steroid-sparing immunosuppressive therapies have not been convincingly effective, but case series have suggested that the interleukin-6 receptor antagonist tocilizumab (Actemra) effectively treats patients with GCA.
In …